

# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

<b>1: Authorisation Number</b>	UK MIA(IMP) 21584
<b>2: Name of authorisation holder</b>	UNIVERSITY OF OXFORD CLINICAL BIOMANUFACTURING FACILITY, OLD ROAD, HEADINGTON, OXFORD, OX3 7JT, UNITED KINGDOM
<b>3: Address(es) of manufacturing site(s)</b>	UNIVERSITY OF OXFORD, GIBSON BUILDING, GROUND FLOOR, RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD, OXFORD, OX2 6GG, UNITED KINGDOM
<b>4: Legally registered address of authorisation holder</b>	UNIVERSITY OF OXFORD, GIBSON BUILDING, GROUND FLOOR, RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD, OXFORD, OX2 6GG, UNITED KINGDOM
<b>5: Scope of authorisation and dosage forms</b>	ANNEX 1 and/ or ANNEX 2
<b>6: Legal Basis of authorisation</b>	Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]
<b>7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation</b>	Confidential
<b>8: Authorisation Date</b>	02/01/2025
<b>9: Annexes attached</b>	Annex 1 and/or Annex 2

### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

**CLINICAL BIOMANUFACTURING FACILITY, OLD ROAD, HEADINGTON, OXFORD, OX3 7JT, UNITED KINGDOM**

Human Investigational Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1) IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)
<b>Part 1 - MANUFACTURING OPERATIONS</b> <b>[ 1.1 ] Sterile Investigational Medicinal Products</b> [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) [ 1.1.1.1 ] Large volume liquids

[ 1.1.1.4 ] Small volume liquids

[ 1.1.1.6 ] Other aseptically prepared products

Adjuvants, preparation of aseptic membranes or matrices to air dry vaccines

**[ 1.2 ] Non-sterile investigational medicinal products**

[ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms)

[ 1.2.1.5 ] Liquids for external use

[ 1.2.1.6 ] Liquids for internal use

[ 1.2.2 ] Batch certification

**[ 1.3 ] Biological investigational medicinal products**

[ 1.3.1 ] Biological medicinal products

[ 1.3.1.1 ] Blood products

[ 1.3.1.2 ] Immunological products

[ 1.3.1.3 ] Cell therapy products

[ 1.3.1.4 ] Gene therapy products

[ 1.3.1.5 ] Biotechnology products

[ 1.3.1.6 ] Human or animal extracted products

[ 1.3.1.8 ] Other biological medicinal products

SiRNA, adjuvants, biological challenge agents

[ 1.3.2 ] Batch certification

[ 1.3.2.1 ] Blood products

[ 1.3.2.2 ] Immunological products

[ 1.3.2.3 ] Cell therapy products

[ 1.3.2.4 ] Gene therapy products

[ 1.3.2.5 ] Biotechnology products

[ 1.3.2.6 ] Human or animal extracted products

[ 1.3.2.8 ] Other biological medicinal products

SiRNA, adjuvants, biological challenge agents

**[ 1.4 ] Other investigational medicinal products or manufacturing activity**

[ 1.4.1 ] Manufacture of:

[ 1.4.1.3 ] Other

Importation of QP-certified IMPs from a country on the 'approved country for import list'

[ 1.4.2 ] Sterilisation of active substances/excipients/finished products:

[ 1.4.2.1 ] Filtration

**[ 1.5 ] Packaging**

[ 1.5.2 ] Secondary packaging

**[ 1.6 ] Quality control testing**

[ 1.6.2 ] Microbiological: non-sterility

[ 1.6.3 ] Chemical/Physical

[ 1.6.4 ] Biological

**Part 2 - IMPORTATION OF MEDICINAL PRODUCTS**

**[ 2.1 ] Quality control testing of imported medicinal products**

[ 2.1.2 ] Microbiological: non-sterility

[ 2.1.3 ] Chemical/Physical

[ 2.1.4 ] Biological

**[ 2.2 ] Batch certification of imported medicinal products**

[ 2.2.1 ] Sterile Products

- [ 2.2.1.1 ] Aseptically prepared
- [ 2.2.1.2 ] Terminally sterilised
- [ 2.2.2 ] Non-sterile products
- [ 2.2.3 ] Biological medicinal products
  - [ 2.2.3.1 ] Blood products
  - [ 2.2.3.2 ] Immunological products
  - [ 2.2.3.3 ] Cell therapy products
  - [ 2.2.3.4 ] Gene therapy products
  - [ 2.2.3.5 ] Biotechnology products
  - [ 2.2.3.6 ] Human or animal extracted products
  - [ 2.2.3.8 ] Other biological medicinal products  
SiRNA, adjuvants, biological challenge agents

**[ 2.3 ] Other Importation Activities**

- [ 2.3.1 ] Site of Physical Importation
- [ 2.3.2 ] Importation of Intermediate which undergoes further processing
- [ 2.3.3 ] Biological Active Substance
- [ 2.3.4 ] Other  
Importation of QP-certified IMPs from a country on the 'approved country for import list'

**SCOPE OF AUTHORISATION**

**Annex 2**

Name and address of the site:

**UNIVERSITY OF OXFORD**, GIBSON BUILDING, GROUND FLOOR, RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD, OXFORD, OX2 6GG, UNITED KINGDOM

Human Investigational Medicinal Products

Authorised Operations

MANUFACTURING OPERATIONS (according to part 1)  
IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

**Part 1 - MANUFACTURING OPERATIONS**

**[ 1.2 ] Non-sterile investigational medicinal products**

- [ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms)
  - [ 1.2.1.1 ] Capsules, hard shell
  - [ 1.2.1.2 ] Capsules, soft shell

**[ 1.5 ] Packaging**

- [ 1.5.2 ] Secondary packaging

**Part 2 - IMPORTATION OF MEDICINAL PRODUCTS**

**[ 2.2 ] Batch certification of imported medicinal products**

- [ 2.2.2 ] Non-sterile products

**[ 2.3 ] Other Importation Activities**

- [ 2.3.1 ] Site of Physical Importation

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA